Locations
Zürich, Switzerland
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Other
founded in
2019
Araris Biotech AG is a pioneering biotechnology company focused on developing a novel antibody-drug conjugate (ADC) linker technology. Their proprietary platform allows for the rapid and efficient attachment of drug payloads to off-the-shelf antibodies without the need for complex engineering, resulting in highly stable and effective ADC therapies. This innovative approach addresses common issues in current ADC technologies, such as poor stability and high heterogeneity, by enabling site-specific conjugation that maintains the antibody's original performance. With a strong investor backing and a commitment to advancing cancer therapies, Araris is positioned to make a significant impact in the biopharmaceutical market.
Something looks off?